Conclusions : KSI-101 demonstrated meaningful visual and anatomical improvements in patients with MESI in the APEX Study • MESI: group of diseases with a shared pathophysiology — inflammation & BRB disruption • Treatment with KSI-101 in MESI patients in APEX, 12-week analyses: ‒ Robust anatomic and visual responses to date ‒ Half of patients achieved a ≥15 letter gain. ‒ >90% resolution of both IRF & SRF by Week 8 ‒ Consistent response with different underlying etiologies • Two Phase 3 trials of KSI-101 in MESI actively enrolling PEAK Moderate to severe edema with moderate to severe vision impairment Mild edema with any vision impairment Moderate to severe edema with good vision PINNACLE PEAK: NCT06990399. PINNACLE: NCT06996080 Key inclusion criteria • Macular edema secondary to inflammation (MESI) • Diagnosis of active or inactive non-infectious intraocular inflammation, acute or chronic. • Active leakage as evidenced by fluorescein angiogram • OCT CST of ≥320 microns • BCVA score ≤78 and ≥25 (~20/25 to 20/320 Snellen) VEGF IL-6 IL-6 KSI-101 PEAK and PINNACLE are actively enrolling 13